CN1839975A - 一种治疗痔疮的药物及其制备方法 - Google Patents
一种治疗痔疮的药物及其制备方法 Download PDFInfo
- Publication number
- CN1839975A CN1839975A CN 200610042007 CN200610042007A CN1839975A CN 1839975 A CN1839975 A CN 1839975A CN 200610042007 CN200610042007 CN 200610042007 CN 200610042007 A CN200610042007 A CN 200610042007A CN 1839975 A CN1839975 A CN 1839975A
- Authority
- CN
- China
- Prior art keywords
- grams
- group
- present
- add
- radix
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 8
- 239000003814 drug Substances 0.000 title claims description 41
- 229940079593 drug Drugs 0.000 title description 18
- 208000014617 hemorrhoid Diseases 0.000 claims abstract description 37
- 238000002360 preparation method Methods 0.000 claims abstract description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 36
- 239000007788 liquid Substances 0.000 claims description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 22
- 239000000341 volatile oil Substances 0.000 claims description 20
- 239000000284 extract Substances 0.000 claims description 13
- 238000011282 treatment Methods 0.000 claims description 11
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 9
- 239000003921 oil Substances 0.000 claims description 7
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 6
- 239000012567 medical material Substances 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- 238000004321 preservation Methods 0.000 claims description 6
- 238000005303 weighing Methods 0.000 claims description 6
- 239000002994 raw material Substances 0.000 claims description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 3
- 239000004141 Sodium laurylsulphate Substances 0.000 claims description 3
- 238000004821 distillation Methods 0.000 claims description 3
- 230000001804 emulsifying effect Effects 0.000 claims description 3
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 claims description 3
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 claims description 3
- 238000000605 extraction Methods 0.000 claims description 3
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 claims description 3
- GYCKQBWUSACYIF-UHFFFAOYSA-N o-hydroxybenzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 claims description 3
- 238000012856 packing Methods 0.000 claims description 3
- 238000001556 precipitation Methods 0.000 claims description 3
- 239000000047 product Substances 0.000 claims description 3
- 238000010992 reflux Methods 0.000 claims description 3
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- 239000006228 supernatant Substances 0.000 claims description 3
- 239000003871 white petrolatum Substances 0.000 claims description 3
- 239000000203 mixture Substances 0.000 abstract description 5
- 244000170916 Paeonia officinalis Species 0.000 abstract 2
- 235000006484 Paeonia officinalis Nutrition 0.000 abstract 2
- 241000213006 Angelica dahurica Species 0.000 abstract 1
- 244000183685 Citrus aurantium Species 0.000 abstract 1
- 235000007716 Citrus aurantium Nutrition 0.000 abstract 1
- 241000229179 Ledebouriella Species 0.000 abstract 1
- 235000003417 Plumeria rubra f acutifolia Nutrition 0.000 abstract 1
- 244000040691 Plumeria rubra f. acutifolia Species 0.000 abstract 1
- 240000004534 Scutellaria baicalensis Species 0.000 abstract 1
- 235000017089 Scutellaria baicalensis Nutrition 0.000 abstract 1
- 235000013399 edible fruits Nutrition 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000003981 vehicle Substances 0.000 description 37
- 241000699670 Mus sp. Species 0.000 description 30
- 239000002674 ointment Substances 0.000 description 27
- 241000402754 Erythranthe moschata Species 0.000 description 19
- 241000699666 Mus <mouse, genus> Species 0.000 description 17
- 230000000694 effects Effects 0.000 description 15
- 241000283973 Oryctolagus cuniculus Species 0.000 description 13
- 208000025865 Ulcer Diseases 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 230000002401 inhibitory effect Effects 0.000 description 10
- 231100000397 ulcer Toxicity 0.000 description 10
- 230000000202 analgesic effect Effects 0.000 description 9
- 230000003110 anti-inflammatory effect Effects 0.000 description 9
- 239000008280 blood Substances 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 108010006464 Hemolysin Proteins Proteins 0.000 description 7
- 208000002193 Pain Diseases 0.000 description 7
- 208000000114 Pain Threshold Diseases 0.000 description 7
- 239000003228 hemolysin Substances 0.000 description 7
- 230000036407 pain Effects 0.000 description 7
- 230000037040 pain threshold Effects 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 206010053567 Coagulopathies Diseases 0.000 description 6
- UILPJVPSNHJFIK-UHFFFAOYSA-N Paeonol Chemical compound COC1=CC=C(C(C)=O)C(O)=C1 UILPJVPSNHJFIK-UHFFFAOYSA-N 0.000 description 6
- 206010057249 Phagocytosis Diseases 0.000 description 6
- 230000035602 clotting Effects 0.000 description 6
- 231100000915 pathological change Toxicity 0.000 description 6
- 230000036285 pathological change Effects 0.000 description 6
- 230000008782 phagocytosis Effects 0.000 description 6
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 5
- 229930182566 Gentamicin Natural products 0.000 description 5
- IPQKDIRUZHOIOM-UHFFFAOYSA-N Oroxin A Natural products OC1C(O)C(O)C(CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IPQKDIRUZHOIOM-UHFFFAOYSA-N 0.000 description 5
- 241000191967 Staphylococcus aureus Species 0.000 description 5
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 5
- 208000027418 Wounds and injury Diseases 0.000 description 5
- IKIIZLYTISPENI-ZFORQUDYSA-N baicalin Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IKIIZLYTISPENI-ZFORQUDYSA-N 0.000 description 5
- 229960003321 baicalin Drugs 0.000 description 5
- AQHDANHUMGXSJZ-UHFFFAOYSA-N baicalin Natural products OC1C(O)C(C(O)CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 AQHDANHUMGXSJZ-UHFFFAOYSA-N 0.000 description 5
- 230000023597 hemostasis Effects 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- -1 triterpenoid compound Chemical class 0.000 description 5
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 4
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- 230000036592 analgesia Effects 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 230000000740 bleeding effect Effects 0.000 description 4
- 230000036760 body temperature Effects 0.000 description 4
- 230000004856 capillary permeability Effects 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 description 4
- 206010014025 Ear swelling Diseases 0.000 description 3
- 206010018691 Granuloma Diseases 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 230000007815 allergy Effects 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 229930182470 glycoside Natural products 0.000 description 3
- 230000035876 healing Effects 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- YLTGFGDODHXMFB-UHFFFAOYSA-N isoacetovanillon Natural products COC1=CC=C(C(C)=O)C=C1O YLTGFGDODHXMFB-UHFFFAOYSA-N 0.000 description 3
- 230000004089 microcirculation Effects 0.000 description 3
- MLIBGOFSXXWRIY-UHFFFAOYSA-N paeonol Natural products COC1=CC=C(O)C(C(C)=O)=C1 MLIBGOFSXXWRIY-UHFFFAOYSA-N 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 description 2
- 239000001606 7-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-2-(4-hydroxyphenyl)chroman-4-one Substances 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 240000001624 Espostoa lanata Species 0.000 description 2
- 235000009161 Espostoa lanata Nutrition 0.000 description 2
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 description 2
- AXVZFRBSCNEKPQ-UHFFFAOYSA-N N-methyltyramine Chemical compound CNCCC1=CC=C(O)C=C1 AXVZFRBSCNEKPQ-UHFFFAOYSA-N 0.000 description 2
- YKRGDOXKVOZESV-WRJNSLSBSA-N Paeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@]1(C[C@@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C)OC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-WRJNSLSBSA-N 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000000702 anti-platelet effect Effects 0.000 description 2
- 230000001754 anti-pyretic effect Effects 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- UAHWPYUMFXYFJY-UHFFFAOYSA-N beta-myrcene Chemical compound CC(C)=CCCC(=C)C=C UAHWPYUMFXYFJY-UHFFFAOYSA-N 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 239000000812 cholinergic antagonist Substances 0.000 description 2
- APSNPMVGBGZYAJ-GLOOOPAXSA-N clematine Natural products COc1cc(ccc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2 APSNPMVGBGZYAJ-GLOOOPAXSA-N 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 229930003944 flavone Natural products 0.000 description 2
- 235000011949 flavones Nutrition 0.000 description 2
- 150000002338 glycosides Chemical class 0.000 description 2
- 239000008941 guipiwan Substances 0.000 description 2
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 description 2
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 description 2
- 229940025878 hesperidin Drugs 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- IYRMWMYZSQPJKC-UHFFFAOYSA-N kaempferol Chemical compound C1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 IYRMWMYZSQPJKC-UHFFFAOYSA-N 0.000 description 2
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 2
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 2
- DFPMSGMNTNDNHN-ZPHOTFPESA-N naringin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](OC=2C=C3O[C@@H](CC(=O)C3=C(O)C=2)C=2C=CC(O)=CC=2)O[C@H](CO)[C@@H](O)[C@@H]1O DFPMSGMNTNDNHN-ZPHOTFPESA-N 0.000 description 2
- 229930019673 naringin Natural products 0.000 description 2
- 229940052490 naringin Drugs 0.000 description 2
- ARGKVCXINMKCAZ-UZRWAPQLSA-N neohesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O[C@H]3[C@@H]([C@H](O)[C@@H](O)[C@H](C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UZRWAPQLSA-N 0.000 description 2
- 239000009835 oxypaeoniflora Substances 0.000 description 2
- FCHVXNVDFYXLIL-QYDSDWLYSA-N oxypaeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@@]1(C[C@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C)OC(=O)C1=CC=C(O)C=C1 FCHVXNVDFYXLIL-QYDSDWLYSA-N 0.000 description 2
- RLXWQODPAWIVOI-UHFFFAOYSA-N oxypaeoniflorin Natural products OCC1OC(OC23CC4C5(O)CC2OC(O5)C34COC(=O)c6ccc(O)cc6)C(O)C(O)C1O RLXWQODPAWIVOI-UHFFFAOYSA-N 0.000 description 2
- 206010033675 panniculitis Diseases 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 238000005057 refrigeration Methods 0.000 description 2
- 230000002048 spasmolytic effect Effects 0.000 description 2
- 210000004304 subcutaneous tissue Anatomy 0.000 description 2
- OMDQUFIYNPYJFM-XKDAHURESA-N (2r,3r,4s,5r,6s)-2-(hydroxymethyl)-6-[[(2r,3s,4r,5s,6r)-4,5,6-trihydroxy-3-[(2s,3s,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]methoxy]oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@H](O)[C@H](O)O1 OMDQUFIYNPYJFM-XKDAHURESA-N 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 description 1
- IQVQXVFMNOFTMU-FLIBITNWSA-N (Z)-ligustilide Chemical compound C1CC=CC2=C1C(=C/CCC)/OC2=O IQVQXVFMNOFTMU-FLIBITNWSA-N 0.000 description 1
- XFSBVAOIAHNAPC-XTHSEXKGSA-N 16-Ethyl-1alpha,6alpha,19beta-trimethoxy-4-(methoxymethyl)-aconitane-3alpha,8,10alpha,11,18alpha-pentol, 8-acetate 10-benzoate Chemical compound O([C@H]1[C@]2(O)C[C@H]3[C@@]45C6[C@@H]([C@@]([C@H]31)(OC(C)=O)[C@@H](O)[C@@H]2OC)[C@H](OC)[C@@H]4[C@]([C@@H](C[C@@H]5OC)O)(COC)CN6CC)C(=O)C1=CC=CC=C1 XFSBVAOIAHNAPC-XTHSEXKGSA-N 0.000 description 1
- SNJVNAXLTOIYQN-XQCQZFFBSA-N 3-[4-[(2s,3r,4s,5s,6r)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxyphenyl]-5,7-dihydroxychromen-4-one Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(C=2C(C3=C(O)C=C(O)C=C3OC=2)=O)C=C1 SNJVNAXLTOIYQN-XQCQZFFBSA-N 0.000 description 1
- LATYEZNGPQKAIK-UHFFFAOYSA-N 6'-O-benzoylpaeoniflorin Natural products O1C(C)(C2(CC34)OC5C(C(O)C(O)C(COC(=O)C=6C=CC=CC=6)O5)O)CC3(O)OC1C24COC(=O)C1=CC=CC=C1 LATYEZNGPQKAIK-UHFFFAOYSA-N 0.000 description 1
- XFSBVAOIAHNAPC-UHFFFAOYSA-N Aconitin Natural products CCN1CC(C(CC2OC)O)(COC)C3C(OC)C(C(C45)(OC(C)=O)C(O)C6OC)C1C32C4CC6(O)C5OC(=O)C1=CC=CC=C1 XFSBVAOIAHNAPC-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- LATYEZNGPQKAIK-HRCYFWENSA-N Benzoylpaeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@]1(C[C@@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](COC(=O)C=2C=CC=CC=2)O1)O)C)OC(=O)C1=CC=CC=C1 LATYEZNGPQKAIK-HRCYFWENSA-N 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- 102100034279 Calcium-binding mitochondrial carrier protein Aralar2 Human genes 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- UBSCDKPKWHYZNX-UHFFFAOYSA-N Demethoxycapillarisin Natural products C1=CC(O)=CC=C1OC1=CC(=O)C2=C(O)C=C(O)C=C2O1 UBSCDKPKWHYZNX-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- 229920000926 Galactomannan Polymers 0.000 description 1
- SNJVNAXLTOIYQN-CWBZKLBCSA-N Genistein 4'-O-neohesperidoside Natural products O([C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@@H]1Oc1ccc(C=2C(=O)c3c(O)cc(O)cc3OC=2)cc1)[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](C)O1 SNJVNAXLTOIYQN-CWBZKLBCSA-N 0.000 description 1
- ZSBXGIUJOOQZMP-UHFFFAOYSA-N Isomatrine Natural products C1CCC2CN3C(=O)CCCC3C3C2N1CCC3 ZSBXGIUJOOQZMP-UHFFFAOYSA-N 0.000 description 1
- ZSBXGIUJOOQZMP-JLNYLFASSA-N Matrine Chemical compound C1CC[C@H]2CN3C(=O)CCC[C@@H]3[C@@H]3[C@H]2N1CCC3 ZSBXGIUJOOQZMP-JLNYLFASSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- AVIUTYMRHHBXPB-UXXRCYHCSA-N Paeonoside Natural products COC1=CC=C(C(C)=O)C(O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=C1 AVIUTYMRHHBXPB-UXXRCYHCSA-N 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
- 241000607762 Shigella flexneri Species 0.000 description 1
- 206010058679 Skin oedema Diseases 0.000 description 1
- AAGFPTSOPGCENQ-UHFFFAOYSA-N Sophocarpin I Natural products C1CCC2CN3C(=O)C=CCC3C3C2N1CCC3 AAGFPTSOPGCENQ-UHFFFAOYSA-N 0.000 description 1
- IGXQFUGORDJEST-UHFFFAOYSA-N Sophocarpine Natural products O=C1C=CCC2C3CCCC4CCCC(CN12)C34 IGXQFUGORDJEST-UHFFFAOYSA-N 0.000 description 1
- 241000219784 Sophora Species 0.000 description 1
- SNJVNAXLTOIYQN-UHFFFAOYSA-N Sophorabioside Natural products CC1OC(OC2C(Oc3ccc(cc3)-c3coc4cc(O)cc(O)c4c3=O)OC(CO)C(O)C2O)C(O)C(O)C1O SNJVNAXLTOIYQN-UHFFFAOYSA-N 0.000 description 1
- ISQRJFLLIDGZEP-KJRRRBQDSA-N Sophoricoside Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O1)c1ccc(C=2C(=O)c3c(O)cc(O)cc3OC=2)cc1 ISQRJFLLIDGZEP-KJRRRBQDSA-N 0.000 description 1
- ISQRJFLLIDGZEP-CMWLGVBASA-N Sophoricoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(C=2C(C3=C(O)C=C(O)C=C3OC=2)=O)C=C1 ISQRJFLLIDGZEP-CMWLGVBASA-N 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- HIMJIPRMECETLJ-UHFFFAOYSA-N Wogonin Natural products COc1cc(O)c(O)c2C(=O)C=C(Oc12)c3ccccc3 HIMJIPRMECETLJ-UHFFFAOYSA-N 0.000 description 1
- LNOHXHDWGCMVCO-UHFFFAOYSA-N Wogonoside Natural products C1=C(O)C(C(C=C(O2)C=3C=CC=CC=3)=O)=C2C(OC)=C1OC1OC(C(O)=O)C(O)C(O)C1O LNOHXHDWGCMVCO-UHFFFAOYSA-N 0.000 description 1
- IQVQXVFMNOFTMU-DHZHZOJOSA-N Z-ligustilide Natural products C1CC=CC2=C1C(=C/CCC)\OC2=O IQVQXVFMNOFTMU-DHZHZOJOSA-N 0.000 description 1
- 229940039750 aconitine Drugs 0.000 description 1
- STDXGNLCJACLFY-UHFFFAOYSA-N aconitine Natural products CCN1CC2(COC)C(O)CC(O)C34C5CC6(O)C(OC)C(O)C(OC(=O)C)(C5C6OC(=O)c7ccccc7)C(C(OC)C23)C14 STDXGNLCJACLFY-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- VIWQCBZFJFSCLC-UHFFFAOYSA-N alpha-benzoyloxypaeoniflorin Natural products O1C(C)(C2(CC34)OC5C(C(O)C(O)C(COC(=O)C=6C=CC=CC=6)O5)O)CC3(O)OC1C24COC(=O)C1=CC=C(O)C=C1 VIWQCBZFJFSCLC-UHFFFAOYSA-N 0.000 description 1
- VYBREYKSZAROCT-UHFFFAOYSA-N alpha-myrcene Natural products CC(=C)CCCC(=C)C=C VYBREYKSZAROCT-UHFFFAOYSA-N 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000000146 antalgic effect Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 230000001139 anti-pruritic effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229930006722 beta-pinene Natural products 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- ZFXVRMSLJDYJCH-UHFFFAOYSA-N calcium magnesium Chemical compound [Mg].[Ca] ZFXVRMSLJDYJCH-UHFFFAOYSA-N 0.000 description 1
- 230000003153 cholinolytic effect Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 108010084210 citrin Proteins 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 1
- 229940114124 ferulic acid Drugs 0.000 description 1
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 1
- 235000001785 ferulic acid Nutrition 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 229930182486 flavonoid glycoside Natural products 0.000 description 1
- 150000007955 flavonoid glycosides Chemical class 0.000 description 1
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000005176 gastrointestinal motility Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 235000006539 genistein Nutrition 0.000 description 1
- 229940045109 genistein Drugs 0.000 description 1
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 description 1
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 description 1
- AVIUTYMRHHBXPB-UHFFFAOYSA-N glucopaeonol Natural products COC1=CC=C(C(C)=O)C(OC2C(C(O)C(O)C(CO)O2)O)=C1 AVIUTYMRHHBXPB-UHFFFAOYSA-N 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 229950009858 glucosulfone Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 235000008777 kaempferol Nutrition 0.000 description 1
- XFFQVRFGLSBFON-DEFKTLOSSA-N kaempferol 3,7-di-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)=C(C=3C=CC(O)=CC=3)OC2=C1 XFFQVRFGLSBFON-DEFKTLOSSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 229940087305 limonene Drugs 0.000 description 1
- 235000001510 limonene Nutrition 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229930014456 matrine Natural products 0.000 description 1
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 229940105623 neo-synephrine Drugs 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000008265 rhamnosides Chemical class 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- AAGFPTSOPGCENQ-JLNYLFASSA-N sophocarpine Chemical compound C1CC[C@H]2CN3C(=O)C=CC[C@@H]3[C@@H]3[C@H]2N1CCC3 AAGFPTSOPGCENQ-JLNYLFASSA-N 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- XLTFNNCXVBYBSX-UHFFFAOYSA-N wogonin Chemical compound COC1=C(O)C=C(O)C(C(C=2)=O)=C1OC=2C1=CC=CC=C1 XLTFNNCXVBYBSX-UHFFFAOYSA-N 0.000 description 1
- LNOHXHDWGCMVCO-NTKSAMNMSA-N wogonin 7-O-beta-D-glucuronide Chemical compound C1=C(O)C(C(C=C(O2)C=3C=CC=CC=3)=O)=C2C(OC)=C1O[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LNOHXHDWGCMVCO-NTKSAMNMSA-N 0.000 description 1
- WTARULDDTDQWMU-UHFFFAOYSA-N β-pinene Chemical compound C1C2C(C)(C)C1CCC2=C WTARULDDTDQWMU-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
组别 | 剂量(g/kg) | 耳肿胀度(mg) |
本发明大剂量组本发明中剂量组本发明小剂量组马应龙麝香痔疮膏组赋形剂组 | 1.060.530.270.42等面积 | 14.0±3.811.7±3.99.3±4.512.5±4.716.5±3.5 |
组别 | 剂量(g/kg) | 吸收度(OD值) |
本发明大剂量组本发明中剂量组本发明小剂量组马应龙麝香痔疮膏组赋形剂组 | 1.060.530.270.42等面积 | 0.064±0.0180.085±0.0190.083±0.0190.095±0.0140.133±0.042 |
组别 | 剂量(g/kg) | 体重(g) | 耳肿胀度(mg) |
本发明大剂量组本发明中剂量组本发明小剂量组马应龙麝香痔疮膏组赋形剂组 | 0.530.270.130.21等面积 | 194.5±8.4197.0±8.7196.0±8.6195.7±9.9200.2±8.0 | 17.1±1.917.3±1.918.1±1.418.2±1.421.2±1.2 |
组别 | 剂量(g/kg) | 药前痛阈值 | 0.5h痛阈值 | 1h痛阈值 | 1.5h痛阈值 |
本发明大剂量组本发明中剂量组本发明小剂量组马应龙麝香痔疮膏组赋形剂组 | 1.060.530.2650.42等面积 | 19.9±4.419.9±4.119.9±4.420.2±4.020.2±4.0 | 34.4±13.429.9±9.731.7±11.336.9±13.7520.2±14.1 | 36.0±15.029.4±15.023.8±9.530.3±13.320.4±10.2 | 25.3±9.526.4±6.226.0±11.121.2±10.021.6±9.7 |
组别 | 剂量(g/kg) | 潜伏期(min) | 耳肿胀度(mg) |
本发明大剂量组本发明中剂量组本发明小剂量组马应龙麝香痔疮膏组赋形剂组 | 1.060.530.270.42等面积 | 6.5±2.85.0±2.88.7±2.14.7±3.24.2±1.2 | 25.1±18.833.9±18.233.4±12.328.2±18.648.6±13.3 |
组别 | 剂量(g/kg) | 致热后不同时间体温变化(℃) | |||||
3h | 4h | 5h | 6h | 7h | 8h | ||
本发明大剂量组本发明中剂量组本发明小剂量组马应龙麝香痔疮膏组复方乙酰水杨酸组赋形剂组 | 0.420.210.110.170.017等面积 | 0.73±0.421.03±0.521.03±0.701.30±0.610.18±0.171.02±0.56 | 0.78±0.100.95±0.400.92±0.281.06±0.460.22±0.161.12±0.45 | 0.60±0.301.13±0.391.00±0.391.10±0.330.12±0.151.12±0.38 | 0.50±0.271.07±0.461.17±0.311.03±0.360.18±0.101.10±0.44 | 0.45±0.461.0±0.470.73±0.300.67±0.340.35±0.270.80±0.24 | 0.42±0.350.87±0.410.44±0.340.58±0.440.47±0.220.53±0.21 |
组别 | 剂量(g/kg) | OD值 |
本发明大剂量组本发明中剂量组本发明小剂量组马应龙麝香痔疮膏组人参归脾丸组赋形剂组 | 1.060.530.270.421.5等面积 | 0.147±0.0630.309±0.1320.494±0.1420.408±0.1820.469±0.1860.348±0.055 |
组别 | 剂量(g/kg) | OD值 |
本发明大剂量组本发明中剂量组本发明小剂量组马应龙麝香痔疮膏组人参归脾丸组赋形剂组 | 1.060.530.270.421.5等面积 | 0.116±0.0370.126±0.0440.195±0.0430.165±0.0630.390±0.1610.253±0.088 |
组别 | 剂量(g/kg) | 凝血时间 |
本发明大剂量组本发明中剂量组本发明小剂量组马应龙麝香痔疮膏组赋形剂组 | 1.060.530.270.42等面积 | 1.6±0.51.7±0.82.3±0.61.4±0.52.2±0.7 |
组别 | 剂量(g/kg) | 出血时间 |
本发明大剂量组本发明中剂量组本发明小剂量组马应龙麝香痔疮膏组赋形剂组 | 1.060.530.270.42等面积 | 3.1±1.22.8±1.34.1±1.63.4±1.45.7±2.2 |
组别 | 剂量(g/kg) | 相对数值 |
本发明大剂量组本发明中剂量组本发明小剂量组马应龙麝香痔疮膏组赋形剂组 | 1.060.530.270.42等面积 | 25.17±1.8024.47±1.9522.46±2.0722.52±2.1320.38±2.03 |
细菌 | 株数 | 药物 | MIC范围(mg/ml,μ/ml) | MIC50(mg/ml,μ/ml) | MIC90(mg/ml,μ/ml) |
金黄色葡萄球菌大肠杆菌绿脓杆菌 | 555 | 本发明硫酸庆大霉素本发明硫酸庆大霉素本发明硫酸庆大霉素 | 0.8-253.1-1006.25-2512.5-1000.8-6.253.1-12.5 | 0.0490.1950.0980.1950.0240.098 | 3.1256.253.12512.50.7813.125 |
细菌 | 株数 | 药物 | MIC(mg/ml,/ml) |
金黄色葡萄球菌(ATCC25923)大肠埃希氏菌(ATCC25922) | 11 | 本发明硫酸庆大霉素本发明硫酸庆大霉素 | 6.25252550 |
组别 | 剂量(g/kg) | 创面坏死及渗出 | 皮肤水肿程度 | 创面表皮新生情况 | |||||||||
0 | 1 | 2 | 3 | 0 | 1 | 2 | 3 | 0 | 1 | 2 | 3 | ||
本发明大剂量组对照赋形剂组本发明中剂量组对照赋形剂组本发明小剂量组对照赋形剂组马应龙麝香痔疮膏组对照赋形剂组 | 0.42等面积0.21等面积0.17等面积0.17等面积 | 30101000 | 30403030 | 03122232 | 03040404 | 50200010 | 12424232 | 02032223 | 02010301 | 10000000 | 40303020 | 13333343 | 03030303 |
组别 | 创面表面坏死及炎性渗出程度 | 创面周围皮肤水肿程度 | 创面表面表皮新生程度 |
本发明大剂量组对照赋形剂组本发明中剂量组对照赋形剂组本发明小剂量组对照赋形剂组马应龙麝香痔疮膏组对照赋形剂组 | 1.50±0.553.50±0.552.00±0.633.70±0.522.17±0.753.50±0.552.33±0.523.67±0.25 | 1.17±0.413.00±0.891.67±0.522.83±0.752.33±0.523.00±0.892.17±0.752.83±0.75 | 2.00±0.633.50±0.552.50±0.553.50±0.552.67±0.523.50±0.552.67±0.523.50±0.55 |
组别 | 剂量(g/kg) | 表皮层病理改变 | 真皮层病理改变 | 皮下组织病理改变 | |||||||||
0 | 1 | 2 | 3 | 0 | 1 | 2 | 3 | 0 | 1 | 2 | 3 | ||
本发明大剂量组对照赋形剂组本发明中剂量组对照赋形剂组本发明小剂量组对照赋形剂组马应龙麝香痔疮膏组对照赋形剂组 | 0.42等面积0.21等面积0.17等面积0.17等面积 | 41313131 | 23323334 | 02030201 | 00000000 | 30202020 | 33423222 | 03031323 | 00010101 | 30101010 | 31412020 | 03123333 | 02030303 |
组别表 | 皮层病理改变 | 真皮层病理改变 | 皮下组织病理改变 |
本发明大剂量组对照赋形剂组本发明中剂量组对照赋形剂组本发明小剂量组对照赋形剂组马应龙麝香痔疮膏组对照赋形剂组 | 0.33±0.521.17±0.750.50±0.551.33±0.820.50±0.551.17±0.750.50±0.551.00±0.63 | 0.50±0.551.50±0.550.67±0.521.83±0.750.83±0.751.83±0.751.00±0.891.83±0.75 | 0.50±0.552.17±0.751.00±0.632.33±0.821.33±0.822.50±0.551.33±0.822.50±0.55 |
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2006100420075A CN100389797C (zh) | 2006-01-12 | 2006-01-12 | 一种治疗痔疮的药物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2006100420075A CN100389797C (zh) | 2006-01-12 | 2006-01-12 | 一种治疗痔疮的药物及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1839975A true CN1839975A (zh) | 2006-10-04 |
CN100389797C CN100389797C (zh) | 2008-05-28 |
Family
ID=37029278
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2006100420075A Active - Reinstated CN100389797C (zh) | 2006-01-12 | 2006-01-12 | 一种治疗痔疮的药物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100389797C (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104435177A (zh) * | 2014-12-22 | 2015-03-25 | 程美兰 | 一种用于治疗痔疮的中药组合物 |
CN109464517A (zh) * | 2019-01-04 | 2019-03-15 | 河南尚工药业有限公司 | 清热解毒儿科外用按摩软膏配方、制备软膏的方法及应用 |
CN110693895A (zh) * | 2019-11-14 | 2020-01-17 | 河南泰丰生物科技有限公司 | 用于治疗痔疮的药物组合物及其制剂 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1141785A (zh) * | 1995-07-28 | 1997-02-05 | 李尼亚 | 消痔丸 |
CN1181858C (zh) * | 2002-04-19 | 2004-12-29 | 殷继兴 | 一种治疗痔疮的中药组合物 |
-
2006
- 2006-01-12 CN CNB2006100420075A patent/CN100389797C/zh active Active - Reinstated
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104435177A (zh) * | 2014-12-22 | 2015-03-25 | 程美兰 | 一种用于治疗痔疮的中药组合物 |
CN109464517A (zh) * | 2019-01-04 | 2019-03-15 | 河南尚工药业有限公司 | 清热解毒儿科外用按摩软膏配方、制备软膏的方法及应用 |
CN110693895A (zh) * | 2019-11-14 | 2020-01-17 | 河南泰丰生物科技有限公司 | 用于治疗痔疮的药物组合物及其制剂 |
Also Published As
Publication number | Publication date |
---|---|
CN100389797C (zh) | 2008-05-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Kong et al. | The genus Litsea in traditional Chinese medicine: an ethnomedical, phytochemical and pharmacological review | |
CN102100720B (zh) | 杏香兔耳风咖啡酰奎宁酸类提取物及其制备与应用 | |
CN102886013A (zh) | 石牛清热口服液 | |
CN104161877A (zh) | 一种用于防治鸡新城疫的复方中药组合物及其制备方法和应用 | |
CN108392591B (zh) | 一种可预防阴道炎的纳米银女士抑菌平衡凝胶 | |
CN101732669A (zh) | 一种用于治疗妇科炎症的中药及其制备方法和应用 | |
CN104208393B (zh) | 一种用于防治鸡传染性支气管炎的中药组合物及其制备方法 | |
CN100389797C (zh) | 一种治疗痔疮的药物及其制备方法 | |
CN101933973B (zh) | 防治肝损伤的药物组合物 | |
CN115025112B (zh) | 白芷多糖在制备防治溃疡性结肠炎的药物中的用途 | |
CN105477126A (zh) | 一种用于治疗抑郁症的中药提取物组合物及其制备方法和应用 | |
CN102793830A (zh) | 一种蛇黄凝胶剂及其制备方法 | |
CN1272027C (zh) | 治疗泌尿系统结石、感染及胆囊结石、胆囊炎的金钱草制剂及其生产方法 | |
CN103272006A (zh) | 白头翁提取液的制备方法及其应用 | |
CN1973853A (zh) | 一种止血镇痛的药物组合物及其制备方法 | |
CN113499425A (zh) | 一种治疗病毒性感冒的组合物及其制备方法 | |
CN107050177A (zh) | 一种用于治疗痤疮的中药组合物及其制备方法 | |
CN1261125C (zh) | 急、慢性鼻炎的中药及其制备方法 | |
CN1291730C (zh) | 一枝黄花在制备治疗和预防sars病毒的药物中的应用 | |
CN111374970A (zh) | 一种具有抗结肠炎活性的组合物及其应用 | |
CN1068782C (zh) | 以栾树提取物为有效组分的抗癌药物及制备方法 | |
CN100343266C (zh) | 一种胡黄连总苷提取物及其在制备肝病药物中的应用和制备方法 | |
CN104546884B (zh) | 一种白木香叶提取物及其制备方法和应用 | |
CN105535246B (zh) | 一种用于治疗牙周炎的现代中药制剂及其制备方法 | |
CN102526181A (zh) | 一种镇咳祛痰的药物组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C19 | Lapse of patent right due to non-payment of the annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
RR01 | Reinstatement of patent right |
Former decision: cessation of patent right due to non-payment of the annual fee Former decision publication date: 20100310 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20160205 Address after: High tech Zone Tianchen road Ji'nan City, Shandong province 250100 No. 666 Patentee after: SHANDONG ZHONGDAQIANFANG PHARMACEUTICAL CO., LTD. Address before: 250002, Shandong province Ji'nan City Central sixteen Li River town Wanshou Road Xing River neighborhood committee health room Patentee before: Gao Dengsheng |